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Background: The human endogenous retrovirus K (HERV-K) has been acquired by the genome of human ancestors
million years ago. It is the most complete of the HERVs with transcriptionally active gag, pol and env genes. Splice
variants of env, which are rec, 1.5 kb transcript and Np9 have been suggested to be tumorigenic. Transcripts of
HERV-K have been detected in a multitude of human cancers. However, no such reports are available concerning
glioblastomas (GBM), the most common malignant brain tumor in adults. Patients have a limited prognosis of
14.6 months in median, despite standard treatment. Therefore, we elucidated whether HERV-K transcripts could be
detected in these tumors and serve as new molecular target for treatment.
Findings: We analyzed human GBM cell lines, tissue samples from patients and primary cell cultures of different
passages for HERV-K full length mRNA and env, rec and 1.5 kb transcripts. While the GBM cell lines U138, U251,
U343 and GaMG displayed weak and U87 strong expression of the full length HERV-K, the splice products could not
be detected, despite a weak expression of env mRNA in U87 cells. Very few tissue samples from patients showed
weak expression of env mRNA, but none of the rec or 1.5 kb transcripts. Primary cells expressed the 1.5 kb transcript
weakly in early passages, but lost HERV-K expression with extended culture time.
Conclusions: These data suggest that HERV-K splice products do not play a role in human malignant gliomas and
therefore, are not suitable as targets for new therapy regimen.
Keywords: Human endogenous retrovirus, HERV-K, Glioblastoma multiforme, Astrocytic tumor, Expression,
Glioblastoma cell line, PCR analysisFindings
Background
Human endogenous retroviruses (HERVs) have been inte-
grated into the genome of human ancestors millions of
years ago after ancient germline infections and passed on
to the following generations. Today these HERVs com-
prise about 8% of the human genome [1]. More than 22
HERV families have been identified [2]. They are classified
according to the tRNA primer-binding site which is, for
example, in the HERV-K family the lysine (K) tRNA [3,4].
Most of the HERV sequences are silenced due to muta-
tions, deletions or other genetic changes. However, HERV-
K is transcriptionally active and able to encode all elements
necessary for a functional retrovirus [5-8]. Nevertheless, to* Correspondence: hagemann_c@ukw.de
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unless otherwise stated.date no infectious HERV-K has been described [9,10]. The
HERV-K genome consists of three genes for functional and
structural proteins which are flanked at the 5′ and the
3′ ends by two long terminal repeat (LTR) sequences
(Figure 1). The LTR regions contain regulatory elements
like enhancer, promoters, polyadenylation signals and
recognition sites for regulatory proteins [11]. The three
main genes of HERVs are gag, env and pol. Gag encodes
structural genes for the formation of the viral matrix
like the capsid structure. The two enzymes reverse tran-
scriptase and integrase are encoded by the gene pol.
The former is necessary for the reverse transcription of
the viral RNA sequence into DNA and the latter for the
integration of this DNA into the genome of the cell. Fi-
nally, env encodes for envelope proteins involved in re-
ceptor recognition and membrane fusion, as well as the
accessory protein Rec [3,5,12]. The latter is a regulatory
factor localized in the nucleus of cells. It has beenLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Organization of HERV-K proviruses, expression pattern and primer localization. The localization of the primer pairs (P1 to P7), the
splice acceptor (SA) and the splice donor (SD), the size of the mRNA in kilo base pairs (kb) and of the corresponding amplicons in base pairs (bp)
are indicated. Modified from [10].
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and induces tumor formation in nude mice [13-15]. An-
other splice product of the env gene is a 1.5 kb transcript
with unknown function. Alongside the HERV-K prototype
structure, a second type of HERV-K proviruses exists. This
type is characterized by a fusion of the pol and the env
genes due to a 292 bp deletion and the loss of the rec gene
[9]. In addition, an open reading frame for the protein
Np9 exists. Like Rec, this protein is found in the nucleus,
and discussed to have oncogenic potential [15-17].
Transcripts of HERVs have been detected in a multitude
of human cancers, but not in the corresponding normal
tissue. These findings have been reviewed comprehen-
sively [2,18]: breast cancer, ovarian cancer, lymphoma,
melanoma, germ line tumors, haematological neoplasms,
sarcoma, bladder cancer, prostate cancer, primary skin tu-
mors and lymphatic metastasis are examples for putative
associations between HERV protein expression and cancer
development [2,18]. Moreover, in blood sera of patients
suffering from melanoma and ovarian cancers even anti-
bodies directed against HERV-K gag and env transcripts
are detectable [10,19-21]. It has been discussed that these
antigens on the surface of cancer cells may be potential
targets for a cancer immune therapy [2,22,23]. Indeed,
antibodies directed against the HERV-K envelope antigen
blocked proliferation of breast cancer cells in vitro and
inhibited tumor growth in mouse xenograft models [24].
Patients with glioblastoma multiforme (GBM), the most
common malignant brain tumor in adults [25], have a very
limited prognosis due to the aggressive local and infiltra-
tive growth pattern of the tumor [26,27]. Standard therapy
comprises neurosurgical tumor resection followed by ir-
radiation and concomitant temozolomide (TMZ) chemo-
therapy and adjuvant TMZ-treatment. Although the
overall outcome of GBM patients has improved with theintroduction of TMZ, the median survival time still does
not exceed 14.6 months after first diagnosis [28]. To over-
come the limitations of current treatment regimen, new
therapeutic targets have to be defined for tumor cell-
detection and eradication. Immunotherapy directed against
tumor specific antigens may be an option and HERV-K
splice products could serve as target. Furthermore, HERV-
K derived proteins may play a role during the tumorigenic
processes. However, to the best of our knowledge, there are
no reports addressing the expression and potential function
of HERV-K in human malignant gliomas. Therefore, we
elucidated whether HERV-K may be expressed and might
play a tumorigenic role in these malignancies.Methods
Tissue samples, cell lines and cell culture. Expression of
HERV-K was analyzed using normal brain and astro-
cytic tumor specimens. Informed consent of the patient
was obtained for the acquisition of tumor material as
approved by the ethics committee of the University of
Würzburg (medical faculty). The samples used have
been discussed in detail in a previous publication [29].
In addition, five human GBM cell lines (U87, U138,
U251, U343 and GaMG) were investigated. The tera-
toma cell line PA1 served as positive control. These cell
lines have been purchased from CLS (Cell Lines Service,
Eppelheim, Germany). Primary cells were isolated from
patients’ GBM tissue samples as described previously
[30]. All GBM cells were grown as reported [31] in
75 cm flasks (Corning, New York, USA) at 37°C in an
atmosphere of 5.0% CO2 and 100% humidity. The PA1
cell line was grown in RPMI-1640 medium supple-
mented with 10% fetal calf serum and 25 μg/ml genta-
mycin (both from Invitrogen, Carlsbad, USA).
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RT-PCR. Trypsinised cells were washed twice with
phosphate-buffered saline. Total mRNA was purified
from the cell pellet and from 30 mg of tissue samples by
the SV Total RNA Isolation System (Promega, Mannheim,
Germany) following the manufacturer’s instructions. These
instructions recommend a DNAse digest to remove con-
taminating genomic DNA. 100 μl DNAse mix (80 μl yellow
core buffer, 10 μl 0.09 M MnCl2, 10 μl DNAse I, all pro-
vided in the kit) were added to each column. The digest
was performed for 30–60 min at 37°C. Then the purifica-
tion was continued according to the manual. Purified RNA
was eluted from the columns with 100 μl RNase-free water
and samples were stored at −80°C. As a test for contamin-
ation with genomic DNA, which would interfere with full
legth HERV-K mRNA detection, a PCR reaction was per-
formed using an aliquot of the mRNA before reverse tran-
scription and the PCR-conditions described below. In case
of positivity the DNAse digest was repeated as described
above for 60 min at 37°C.
One to 5 μg of the total RNA was reverse-transcribed
using the RevertAid H Minus First Strand cDNA Synthe-
sis Kit (Fermentas, Ontario, Canada) and the provided
oligo(dT)18 primer as described elsewhere [29].
The HERV-K expression level was determined by
semiquantitative RT-PCR. The amount of cDNA wasFigure 2 Expression analysis of five human GBM cell lines by semiqua
U251, U343 and GaMG was used for semiquantitative RT-PCR analysis. The
mutant, the spliced envelope (env) mRNA, the double spliced rec and the 1.5
provirus is shown in Figure 1. The length of the cDNA amplicons in base pairs
of the teratoma cell line PA1 was used. The various cDNA concentrations wer
contamination with genomic DNA, which would interfere with full length HER
the mRNA before reverse transcription (Control).normalized to the intensity of the PCR product of the ubi-
quitously expressed gene glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH), which was used as internal
control [32,33]. The primer sequences for GAPDH detec-
tion were sense 5′-GCAGGGGGGAGCCAAAAGGG-3′
and antisense 5′-TGCCAGCCCCAGCGTCAAAG-3′. The
full-length HERV-K virus and different splice variants were
analysed using a set of seven primers corresponding
to HERV-K108/-K10, −K.HOM and related HERV-K
(Figure 1). Details about primer sequences, location of
primer recognition sites within the virus genome and amp-
lified fragment sizes can be found in [10]. Primer combina-
tions P2 + P3, as well as P4 + P5 confirm the expression
of the full length mRNA, while P4 + P5 also distinguish
between the prototype and the deletion mutant. Primer
combinations P2 + P5 and P2 + P6 detect the envelope
sequence and P1 + P7 amplify the double spliced rec and
the 1.5 kb mRNA. The polymerase chain reaction was per-
formed using 0.625 U Dream Taq polymerase (Fermentas,
Ontario, Canada) in each 25 μl reaction, containing 10x
buffer with 25 mM MgCl2 (Fermentas, Ontario, Canada).
For primer combination P1 + P7 1 μl formamid (Eurobio,
Courtaboef Cedex, France) was added to the reaction.
Thermocycle parameters were as follows: 10 min at 94°C;
35 cycles (21 for GAPDH) of 30 sec at 94°C, 30 sec at 60°C
(68°C for GAPDH), 2 min (1 min for GAPDH) at 72°C; andntitative RT-PCR. Total RNA from the five GBM cell lines U87, U138,
primers for detection of the full length HERV-K mRNA, the deletion
kb mRNA are described in [10]. Their localization within the HERV-K
(bp) is shown on the right side of the figure. As positive control (+) cDNA
e normalized to that of the housekeeping gene GAPDH. As a test for
V-K mRNA detection, a PCR reaction was performed using an aliquot of
Figure 3 Expression analysis of HERV-K mRNA splice products in normal brain and human astrocytic tumor samples. Semiquantitative
RT-PCR was used to detect spliced env mRNA, double spliced rec mRNA and 1.5 kb mRNA of HERV-K in three normal brain samples (NB), 13
astrocytoma WHO grade 2 (low grade astrocytoma, LGA) and 17 glioblastoma multiforme (GBM), as described in Figure 2. GAPDH served as
internal loading control for normalization of the cDNA concentrations.
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on 1% agarose gels (Sigma-Aldrich, Steinheim, Germany)
containing 0.07 μg/ml ethidium bromide (Roth, Karlsruhe,
Germany) and photographed using the BioDocAnalyze
digital (Biometra, Göttingen, Germany).
Results and conclusion
Expression of full length HERV-K mRNA and its splice
variants env, rec and 1.5 kb mRNA were analyzed by semi-
quantitative RT-PCR in different human GBM cell lines,
patients’ tissue samples of astrocytic tumors and primary
cell cultures of different passages. The human GBM cell
lines U138, U251, U343 and GaMG displayed weak ex-
pression of the full length HERV-K mRNA (Figure 2),
while U87 cells showed strong expression. While most of
these GBM cell lines have been tested for the first time,
the U87 data confirm already published results [10]. The
detection of full length mRNA was not due to contamin-
ation of the reaction with genomic DNA (Figure 2). How-
ever, the deletion mutant could not be detected in these
cell lines. U87 cells showed a very weak expression of the
689 bp envelope mRNA. All other splice variants were not
detectable in all GBM cell lines tested (Figure 2).Figure 4 Expression analysis of HERV-K mRNA splice products in primar
cell cultures, derived from patients’ biopsies, were passaged 6 times. Total
semiquantitative RT-PCR as described in Figure 2.In patients’ tissue HERV-K expression was tested in a
standardized cDNA panel of three normal brain (NB)
tissue samples, 13 astrocytomas WHO grade 2 (low
grade astrocytoma, LGA) and 17 GBMs (Figure 3). Due
to the limited availability of patients’ tissue, only the
oncogenically relevant splice variants were checked. In
one NB (33%), one LGA (7.7%) and two GBM samples
(11.8%) expression of the env mRNA could be detected.
However, the splice products rec and 1.5 kb mRNA
were not found (Figure 3). This suggests that HERV-K
splice products do not play a role in human glioma
tumorigenic processes and therefore are not suitable as
a therapeutic target.
Since passaging of cells in vitro is able to induce mRNA
and protein expression of certain proteins [34-36], we ana-
lysed a possible induction of HERV-K expression by cell-
passaging. Three primary cell cultures were cultured for 6
passages and HERV-K expression was analysed at passage
2 and passage 6 by semiquantitative RT-PCR (Figure 4).
Although at passage 2 the 1.5 kb mRNA was expressed
very weakly by all three cultures, there was no expression
of any splice product detectable at passage 6 (Figure 4).
This may be due to the culture conditions, which seem toy GBM cells by semiquantitative RT-PCR. Three different primary
RNA was isolated from passage 2 and passage 6 and used for
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that seen in established GBM cell lines.
In summary, we found HERV-K full length mRNA
expressed in human GBM cell lines. However, the splice
variants were neither detectable in GBM cell lines, nor in
most of the patients’ tissue samples from NB, LGA and
GBM. Passaging of primary cells derived from these tu-
mors did not induce HERV-K expression.
Therefore, we conclude that HERV-K, at least the vari-
ants which can be detected with the primer pairs we used,
is - in contrast to several other cancer types [2] - not
expressed in human malignant gliomas, and therefore
probably does not play a role in proliferation and progres-
sion of these tumors. Our findings do not exclude that
other HERVs or other virus types may be involved in
modulating the phenotype of GBM cells. For example, it
has been shown that sequences and viral gene expression
of the human cytomegalovirus (HCMV) can be found in
GBM and may act tumor supportive by interaction with
key signaling pathways [37].
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